JNJ

233.57

-0.17%↓

ISRG

468.36

-5.07%↓

ABT

107.54

+0.67%↑

RDY

13.93

+1.24%↑

NEOG

10.23

-4.03%↓

JNJ

233.57

-0.17%↓

ISRG

468.36

-5.07%↓

ABT

107.54

+0.67%↑

RDY

13.93

+1.24%↑

NEOG

10.23

-4.03%↓

JNJ

233.57

-0.17%↓

ISRG

468.36

-5.07%↓

ABT

107.54

+0.67%↑

RDY

13.93

+1.24%↑

NEOG

10.23

-4.03%↓

JNJ

233.57

-0.17%↓

ISRG

468.36

-5.07%↓

ABT

107.54

+0.67%↑

RDY

13.93

+1.24%↑

NEOG

10.23

-4.03%↓

JNJ

233.57

-0.17%↓

ISRG

468.36

-5.07%↓

ABT

107.54

+0.67%↑

RDY

13.93

+1.24%↑

NEOG

10.23

-4.03%↓

Home・Akcijų sąrašas・Corvus Pharmaceuticals Inc

Corvus Pharmaceuticals Inc

Atidarymo kaina

21.04 -2.09

Pirkti Parduoti

Apžvalga

Akcijų kainos pasikeitimas

24 val.

Dabar

Min

20.98

Max

21.63

Pagrindiniai rodikliai
By Trading Economics
Pajamos	-2.2M -10M
Darbuotojai	31
EBITDA	131K -10M

Rekomendacijos
By TipRanks
Rekomendacijos	Stiprus pirkimas
12 mėnesių prognozė	+51.57% upside

Dividendai
By Dow Jones
Kitas uždarbis	2026-03-24

Rinkos statistika
By TradingEconomics
Rinkos kapitalizacija	1.4B 1.9B
Ankstesnė atidarymo kaina	23.13
Ankstesnė uždarymo kaina	21.04

Techninis įvertinimas

By Trading Central

Pasitikėjimas

Strong Bearish Evidence

3.165 / 3.5827 Palaikymas ir pasipriešinimas

Corvus Pharmaceuticals Inc Grafikas

Ankstesni rezultatai nėra patikimas būsimų rezultatų rodiklis.

Susijusios naujienos

2026-02-03 23:11; UTC

Pagrindinės rinkos jėgos

Įsigijimai, susijungimai, perėmimai

Silicon Laboratories Shares Up On Report of $7 Billion Texas Instruments Acquisition Deal

2026-02-03 23:50; UTC

Rinkos pokalbiai

Global Forex and Fixed Income Roundup: Market Talk

2026-02-03 23:50; UTC

Rinkos pokalbiai

Nikkei May Decline After Hitting All-Time High -- Market Talk

2026-02-03 23:42; UTC

Rinkos pokalbiai

Gold Edges Lower on Possible Technical Correction -- Market Talk

2026-02-03 23:41; UTC

Įsigijimai, susijungimai, perėmimai

KKR Makes AI Play With $10.9B Asia Data-Center Deal

2026-02-03 23:38; UTC

Uždarbis

AMD Sales Climb on Help From Data-Center Business -- Update

2026-02-03 23:29; UTC

Įsigijimai, susijungimai, perėmimai

KKR-Consortium Deal in STT GDC Is One of the Largest Digital-Infrastructure Transactions in Southeast Asia

2026-02-03 23:27; UTC

Įsigijimai, susijungimai, perėmimai

Netflix, Warner Defend Proposed Deal in Senate Hearing -- WSJ

2026-02-03 23:25; UTC

Įsigijimai, susijungimai, perėmimai

KKR-Consortium Expects Deal to Close by Early 2H of 2026

2026-02-03 23:23; UTC

Įsigijimai, susijungimai, perėmimai

KKR Consortium With Singtel to Own 75% and 25% Stake in ST Telemedia Global Data Centres

2026-02-03 23:22; UTC

Įsigijimai, susijungimai, perėmimai

KKR-Led Consortium to Buy Singapore-Based Global Data-Center Provider Valued at S$13.8B

2026-02-03 23:19; UTC

Rinkos pokalbiai

Australia Gold Miners Tipped to Rally Higher -- Market Talk

2026-02-03 23:19; UTC

Rinkos pokalbiai

Global Equities Roundup: Market Talk

2026-02-03 22:56; UTC

Pagrindinės rinkos jėgos

Įsigijimai, susijungimai, perėmimai

Silicon Laboratories Shares Up On Report of $7B Texas Instruments Acquisition Deal

2026-02-03 22:40; UTC

Uždarbis

Amdocs Extends Collaboration With T-Mobile

2026-02-03 22:39; UTC

Uždarbis

Amdocs 1Q Adj EPS $1.81

2026-02-03 22:39; UTC

Uždarbis

Amdocs 1Q Rev $1.16B

2026-02-03 22:39; UTC

Uždarbis

Amdocs 1Q EPS $1.45 >

2026-02-03 22:38; UTC

Uždarbis

Amdocs: Shimie Hortig to Succeed Shuky Sheffer as President and CEO, Effective March 31

2026-02-03 22:30; UTC

Įsigijimai, susijungimai, perėmimai

Bob Iger's Second Time as CEO Wasn't Great for the Stock. He Still Leaves Behind A Strong Legacy. -- Barrons.com

2026-02-03 22:22; UTC

Įsigijimai, susijungimai, perėmimai

Texas Instruments Nearing $7B Deal for Silicon Laboratories, Sources Tell FT

2026-02-03 22:14; UTC

Uždarbis

AMD Expects to Scale AI Business to Tens of Billions in Annual Sales in 2027, CEO Says

2026-02-03 22:13; UTC

Uždarbis

AMD Expects Data-Center Unit Sales to Jump More Than 60% a Year Over Next Three to Five Years, CEO Says

2026-02-03 22:12; UTC

Uždarbis

AMD in Talks With Several Companies About At-Scale, Multi-Year Chip Deployments, CEO Says

2026-02-03 22:10; UTC

Uždarbis

AMD CEO: Eight of 10 Biggest AI Companies Use Instinct Chip to Power Production Workloads

2026-02-03 22:10; UTC

Uždarbis

Blackstone Stock, Alternative Managers, BDCs Dive as Software Woes Infect Private Credit -- Barrons.com

2026-02-03 22:10; UTC

Rinkos pokalbiai

Key Drivers Underpinning Shaw's Bullish View of Gold Intact -- Market Talk

2026-02-03 22:10; UTC

Uždarbis

AMD CEO: Enterprises Are Modernizing Data Centers to Have Compute Needed for New AI Workflows

2026-02-03 22:09; UTC

Uždarbis

AMD CEO: Hyperscalers Expanding Infrastructure to Meet Growing Cloud-Services Demand in AI

2026-02-03 22:09; UTC

Uždarbis

AMD CEO: Demand Accelerated Across Data Center, Gaming and PC

Akcijų palyginimas

Kainos pokytis

Corvus Pharmaceuticals Inc Prognozė

Kainos tikslas

By TipRanks

51.57% į viršų

12 mėnesių prognozė

Vidutinis 31.8 USD 51.57%

Aukščiausias 42 USD

Žemiausias 27 USD

Remiantis 5 „Wall Street“ analitikais, siūlančiais 12 mėnesių tikslines Corvus Pharmaceuticals Inc kainas – Dist per pastaruosius 3 mėnesius.

Bendras įvertinimas

By TipRanks

Stiprus pirkimas

5 ratings

Pirkti

Laikyti

Parduoti

Remiantis 5 analitikų, pateikusių Corvus Pharmaceuticals Inc akcijų reitingus – Dist per pastaruosius 3 mėnesius.

Techninis įvertinimas

By Trading Central

3.165 / 3.5827Palaikymas ir pasipriešinimas

Recent bearish events outweigh bullish events.

All events are bearish.

Bearish events outweigh bullish events.

Finansinės naujienos

Pardavimo ir administravimo išlaidos

Veiklos sąnaudos

Ikimokestinis pelnas

Pardavimai

Pardavimo savikaina

Bendrasis pelnas iš pardavimo

Skolų palūkanų išlaidos

EBITDA

Veiklos pelnas

Apie bendrovę Corvus Pharmaceuticals Inc

Corvus Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of immune modulator product candidates to treat solid cancers, T cell lymphomas, autoimmune, allergic, and infectious diseases. Its lead product candidate is soquelitinib (CPI-818), a selective covalent inhibitor of interleukin 2 inducible T cell kinase (ITK), which is in a multi-center Phase 1/1b clinical trial for the treatment of peripheral T cell lymphoma, solid tumors, and atopic dermatitis. The company is also developing ciforadenant (CPI-444), an oral small molecule antagonist of the A2A receptor that is in Phase 2 clinical trial for the treatment of metastatic renal cell cancer; and mupadolimab (CPI-006), a humanized monoclonal antibody, which is in Phase 1b clinical trial for the treatment of non-small cell lung cancer and head and neck cancer. In addition, it is developing CPI-182, an antibody designed to block inflammation and myeloid suppression that is in investigational new drug application-enabling studies, as well as CPI-935, an adenosine A2B receptor antagonist to prevent fibrosis. Corvus Pharmaceuticals, Inc. has a license afreemnt with Monash University to research, develop, and commercialize certain antibodies directed to CXCR2 for the treatment of human diseases; and Vernalis (R&D) Limited to develop, manufacture, and commercialize products containing certain adenosine receptor antagonists, including ciforadenant, as well as strategic collaboration with Angel Pharmaceuticals Co. Ltd. for the development and commercialization of mupadolimab. Corvus Pharmaceuticals, Inc. was incorporated in 2014 and is based in Burlingame, California.